differentiate AEBA bronchial asthma VS AEBA COPD
Reading File
Finding Sources
Searching PubMed
asthma COPD exacerbation
Searching the Web
GINA 2025 asthma exacerbation GOLD 2025 COPD exacerbation diagnosis clinical features
AEBA (acute exacerbation of bronchial asthma) vs AECOPD (acute exacerbation of COPD)
| Feature | AEBA | AECOPD |
|---|---|---|
| Typical patient | Often younger, but any age; personal/family history of atopy | Usually >40 years; smoking or biomass-fuel/toxic exposure history |
| Baseline disease | Variable, usually reversible airway obstruction | Chronic, persistent airflow limitation, often partly reversible only |
| Onset of worsening | Often rapid, over minutes to hours | Usually gradual, over days, typically <14 days |
| Common trigger | Allergen, viral infection, exercise, cold air, smoke, poor inhaler adherence, NSAIDs in susceptible people | Respiratory viral or bacterial infection, air pollution, smoking, treatment non-adherence; sometimes pneumonia, heart failure, pulmonary embolism |
| Symptoms during flare | Episodic breathlessness, chest tightness, cough, widespread wheeze, often little sputum | Increased baseline dyspnea plus increased cough and sputum volume and/or purulence |
| Sputum | Often absent or scant, mucoid | Usually chronic sputum at baseline; purulent sputum favors bacterial contribution |
| Atopy/upper-airway clues | Eczema, allergic rhinitis, nasal polyps, allergen-related or nocturnal symptoms may be present | Less typical; exposure history and chronic productive cough are more characteristic |
| Examination | Diffuse polyphonic expiratory wheeze, prolonged expiration; severe attack may have “silent chest” | Wheeze with prolonged expiration, reduced breath sounds; barrel chest, hyperinflation, pursed-lip breathing, cyanosis may be present |
| Spirometry when stable | Obstruction with significant variability/reversibility, often bronchodilator rise in FEV1 ≥12% and ≥200 mL | Post-bronchodilator FEV1/FVC <0.70 confirms persistent airflow obstruction |
| Blood tests | Eosinophilia may support type-2/eosinophilic asthma, but is not required | Neutrophilic inflammation is common; eosinophils can identify a subgroup more likely to benefit from corticosteroids |
| ABG in severe illness | Early: low PaCO2 from hyperventilation. A normal or rising PaCO2 is an ominous sign of fatigue and impending respiratory failure. | Hypoxemia with hypercapnia and respiratory acidosis is more common, especially in advanced COPD or severe exacerbations |
| Chest radiograph | Often normal or hyperinflated; mainly done to exclude pneumothorax, pneumonia, edema, etc. | May show hyperinflation/flattened diaphragms; also used to look for pneumonia, pneumothorax, edema |
| Initial treatment overlap | Controlled oxygen, repeated inhaled SABA, add ipratropium if severe, systemic corticosteroid | Controlled oxygen, short-acting bronchodilators (SABA ± ipratropium), systemic corticosteroid |
| Antibiotics | Not routine, unless there is evidence of bacterial infection/pneumonia | Consider when sputum purulence accompanies increased sputum volume and dyspnea, or when ventilatory support is needed |
| Oxygen target | Usually SpO2 93-95% in adults, unless risk of CO2 retention | Usually SpO2 88-92% because excessive oxygen can worsen hypercapnia in susceptible patients |
| Ventilatory support | NIV has a limited/selective role; deterioration may require intubation | NIV is strongly useful when acute hypercapnic respiratory failure with acidosis is present, unless contraindicated |
Fast clinical distinction
Think AEBA when there is a history of variable or allergic airway disease and a sudden wheezy, tight-chested episode with little sputum.
Think AECOPD when an older patient with smoking/biomass exposure and chronic cough develops worsening dyspnea with a change in sputum, especially increased purulence.
Important caveat
Asthma and COPD can coexist, especially in older smokers. Do not label a patient as COPD alone if there are clear asthma features. In a patient with both conditions, inhaled corticosteroid-containing treatment is important because treating asthma only with bronchodilators is unsafe. GINA notes that asthma has variable airflow limitation, whereas COPD requires persistent post-bronchodilator obstruction; the disorders are not mutually exclusive (GINA 2025 report). GOLD defines an exacerbation as worsening dyspnea and/or cough with sputum over less than 14 days (GOLD 2025 pocket guide).
Red flags in either condition
Urgent escalation is needed for altered consciousness, exhaustion, silent chest, cyanosis, hemodynamic instability, severe hypoxemia, rising PaCO2/acidosis, or failure to improve after initial bronchodilator treatment.
This is a shared conversation. Sign in to Orris to start your own chat.